Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PJS-539 in Adult Patients With SARS-CoV-2
NCT05008393Phase 2Completed
- Sponsor
- HCor
- Start
- Sep 2021
- Primary completion
- Feb 2022
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of halofuginone in coronavirus disease 2019 (COVID-19), sponsored by HCor. Started Sep 2021; status: completed.
02
Drugs
halofuginone
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05008393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05008393.